GlaxoSmithKline Pharmaceuticals Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of GlaxoSmithKline Pharmaceuticals Limited generated cash of $5,820,155,000, which is more than the previous year. Cash used in financing activities reached the amount of -$5,614,969,000 last year. Net change in cash is therefore $292,303,000.
Cash Flow
| 2010 | 4.79B | 867.56M | -2.97B |
|---|---|---|---|
| 2011 | 3.35B | 992.21M | -3.94B |
| 2012 | 3.13B | -1.09B | -4.40B |
| 2013 | 2.81B | 1.88B | -4.94B |
| 2016 | 1.39B | 5.00B | -6.38B |
| 2018 | 4.72B | -1.04B | -3.06B |
| 2020 | 4.90B | -568.43M | -4.27B |
| 2021 | 5.77B | 4.18B | -6.96B |
| 2023 | 4.84B | 8.07B | -15.43B |
| 2024 | 5.82B | -847.20M | -5.61B |
GLAXO.NS Cash Flow Statement (2010 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2013 | 2013 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 349.40M | 2.86B | 1.04B | 987.76M | 1.39B | 1.15B | 1.37B | 3.74B | 20.03B | 17.34B |
Operating activities | ||||||||||
Net income | 5.89B | 8.41B | 7.23B | 6.47B | 5.22B | 5.76B | 6.85B | 9.82B | 4.28B | 5.60B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 696.79M | 657.7M | 792.83M | 826.77M | 379.85M | 247.76M | 198.81M | 178.39M | 204.07M | 176.28M |
Stock-based compensation expense | 113.97M | 25.33M | 128.50M | 132.11M | 73.50M | 87.97M | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 113.97M | 25.33M | 128.50M | 132.11M | 73.50M | 87.97M | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -302.68M | 202.28M | -999.34M | -497K | 231.60M | -262.47M | 0 | 0 | 0 | 0 |
Inventories | -650.77M | 747.2M | -467.93M | -677.16M | -743.85M | -1.50B | -618.24M | 473.31M | -507.29M | -282.56M |
Accounts payable | 1.90B | -1.53B | 1.07B | -482.29M | 2.26B | 197.02M | 0 | 0 | 0 | 0 |
Cash generated by operating activities | 5.82B | 4.84B | 5.77B | 4.90B | 4.72B | 1.39B | 2.81B | 3.13B | 3.35B | 4.79B |
Investing activities | ||||||||||
Purchases Of Investments | -58.02B | -52.64B | -33.78B | -11.41B | -10.69B | -19.93B | -21.49B | -22.19B | 0 | 0 |
Investments In Property Plant And Equipment | -312.21M | -440.4M | -442.26M | -1.55B | -4.03B | -2.32B | -582.21M | -390.76M | -420.95M | -213.94M |
Acquisitions Net | 44.69M | 1.94B | 1.8B | 1.55B | 4.03B | 241.25M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -847.20M | 8.07B | 4.18B | -568.43M | -1.04B | 5.00B | 1.88B | -1.09B | 992.21M | 867.56M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | -5.41B | -15.25B | -6.77B | -4.08B | -2.54B | -5.29B | -4.21B | -3.78B | -3.37B | -2.53B |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -181.25M | 0 | -1.53M | -4.06M | -6.06M | -7.42M | -4.50M | -3.11M | -2.56M | -2.56M |
Cash used in financing activities | -5.61B | -15.43B | -6.96B | -4.27B | -3.06B | -6.38B | -4.94B | -4.40B | -3.94B | -2.97B |
Net Change In Cash | 292.30M | -2.51B | 3.00B | 60.34M | 619.71M | 17.58M | -238.46M | -2.36B | 400.51M | 2.68B |
Cash at end of period | 641.71M | 349.4M | 4.05B | 1.04B | 2.01B | 1.17B | 1.13B | 1.37B | 20.43B | 20.03B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |